TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid' Apr 27, 2026 10:48AM
TD Cowen Reiterates Buy Rating on Intellia Therapeutics (NTLA) Feb 26, 2026 01:28PM
Intellia Therapeutics to Participate in Upcoming Investor Conferences Feb 24, 2026 08:00AM
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026' Dec 19, 2025 09:06AM
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress Feb 27, 2025 07:30AM


Jun 3, 2024 12:09PM TD Cowen Reiterates Buy Rating on Intellia Therapeutics (NTLA)
Feb 22, 2024 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
Feb 23, 2023 07:30AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
Aug 4, 2022 11:06AM Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'
Jun 17, 2022 06:22AM Intellia Therapeutics (NTLA) Named Best Smidcap Idea at Cowen
Mar 1, 2022 06:50AM Cowen Reiterates Outperform Rating on Intellia Therapeutics (NTLA)
Jan 31, 2022 05:31AM UPDATE: Cowen Starts Intellia Therapeutics (NTLA) at Outperform
Jun 2, 2020 09:28AM Pre-Open Stock Movers 06/02: (MGI) (WU) (SWBI) Higher; (PUMP) (INVH) (GH) Lower (more...)
Mar 8, 2017 07:36AM Intellia Therapeutics (NTLA) Reports Data Showing Increased Genome Editing Efficiency in Vivo and Durability Results with its CRISPR/Cas9 Technology
Mar 8, 2017 07:30AM Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology
Mar 1, 2017 07:10AM Intellia Therapeutics to Present at March Investor Healthcare Conferences